Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS

BackgroundTimely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients’ quality of life. However, there is a significant lack of studies addressing these events in real-world settings.MethodsTo bridge this gap, we analyzed adverse event...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ke Wang, Junyan Chen, Mingquan Huang, Xinhao Zeng, Xiaoqun Ren, Xiuqiong Liu, Chao Tao, Liuxuan Yang, Jinlu Shang, Meiling Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	Parkinson-like events pharmacovigilance drug safety antiparkinsonian agents adverse event FAERS
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1529260/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
by: Wenwen Zhang, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database
by: Bojing Wang, et al.
Published: (2025-01-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]
by: Yang F, et al.
Published: (2025-02-01)

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS
by: Lin Li
Published: (2025-01-01)

Drug utilization study of antiparkinsonian medication in Romania during 25 years
by: Camelia Bucsa, et al.
Published: (2025-02-01)

Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
by: Luyang Su, et al.
Published: (2024-12-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
by: Muhammed Favas Karimbanathottathil, et al.
Published: (2024-12-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Examining vaccination-related adverse events in frequent neurodegenerative diseases
by: Shabnam Sodagari, et al.
Published: (2025-02-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)